Bleselumab Explained

Type:	mab
Mab Type:	mab
Source:	u
Target:	CD40
Cas Number:	1453067-91-8
Atc Prefix:	none
Chemspiderid:	none
C:	6412
H:	9906
N:	1690
O:	2018
S:	38
Unii:	AS3AZ5R46K
Kegg:	D11357
Synonyms:	ASKP1240

Bleselumab (INN;^[1] development code ASKP1240) is a human monoclonal antibody designed for the prevention of organ transplant rejection.^{[2] [3]}

This drug was developed by Kyowa Kirin Pharmaceutical Development Inc.^[4]

References

1. . International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113 . WHO Drug Information . 29 . 2 . 2015 .
2. Wojciechowski D, Vincenti F . Current status of costimulatory blockade in renal transplantation . Current Opinion in Nephrology and Hypertension . 25 . 6 . 583–590 . November 2016 . 27517137 . 10.1097/MNH.0000000000000268 . 4379881 .
3. Malvezzi P, Jouve T, Rostaing L . Costimulation Blockade in Kidney Transplantation: An Update . Transplantation . 100 . 11 . 2315–2323 . November 2016 . 27472094 . 5084636 . 10.1097/TP.0000000000001344 .
4. https://searchusan.ama-assn.org/undefined/documentDownload?uri=%2Funstructured%2Fbinary%2Fusan%2Fbleselumab.pdf Statement On A Nonproprietary Name Adopted By The USAN Council - Bleselumab